SYRE earnings: a negative outcome, -6.6%

On November 3, 2022, Spyre Therapeutics, Inc. reached its earnings. The result was a negative outcome, and the stock moved -6.6% in the window around the event. It had already run +95.1% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.